Marks latest milestone in company’s previously announced $23 billion investment in US infrastructure ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
First to have delivered at scale, Novartis fortifies leadership in RLT innovation and infrastructure with California facility, additional plans for Florida and Texas ...
Certains résultats ont été masqués, car ils peuvent vous être inaccessibles.
Afficher les résultats inaccessibles
Commentaires